TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Tibosovo (ivosidenib tablets) for oral use Initial U.S. Approval: 2018<\/strong> Note:<\/strong><\/em> Tibosovo (ivosidenib) is a prescription medicine used to treat adults with an IDH1 mutation who have:\u00a0Acute myeloid leukemia (AML) that is either newly-diagnosed or relapsed\/refractory, or\u00a0Locally advanced or metastatic bile duct cancer (cholangiocarcinoma).<\/p>\n Disease Indications-Leukemia, Bile Duct Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cIvosidenib Tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nAcute Myeloid Leukemia (AML)<\/strong>
\n\u2022 Newly-diagnosed AML who are \u2265 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy .
\n\u2022 Relapsed or refractory AML .
\nLocally Advanced or Metastatic Cholangiocarcinoma<\/strong>
\n\u2022 Locally advanced or metastatic cholangiocarcinoma who have been previously treated .<\/p>\nHow To access ivosidenib tablets?<\/h3>\n
\nTo access ivosidenib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Ivosidenib tablets
\nfor oral use Initial U.S. Approval: 2018<\/h2>\nFacts about ivosidenib tablets<\/h4>\n
\nManufacturer-Servier Pharmaceuticals
\nUsage-Oral
\nMedicine Approved By-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n